fda removes tirzepatide Article » Proact Pharmacy Services FDA moves to remove GLP-1

Improved metabolic health Enhances insulin function and stabilizes blood sugar levels

In addition, it highlights the value of treating obesity as a metabolic disease instead of expecting people to make significant progress on lifestyle changes and willpower alone

This brief duration of action limits its therapeutic utility in its natural form, necessitating the development of longer-acting GLP-1 receptor agonists that can provide sustained clinical benefits with less frequent dosing

Tirzepatide is a medicine that is given under the skin once a week, usually through a prefilled injection pen

For many people, the decision comes down to whether the additional weight loss potential justifies the extra cost

PMID: 153 AlmatroodiSAAlsahliMARahmaniAH